Global Immune Technologies Appoints Director

Mar 03, 2011, 06:44 ET from Global Immune Technologies, Inc.

WINDISCHLEUBA, Germany, and MISSOULA, Mont., March 3, 2011 /PRNewswire/ -- The Board of Directors of Global Immune Technologies, Inc. (OTB QB: GIMU) today announces that at a Meeting of the Board of Directors, the meeting elected one new director increasing the size of the board to two members. The new member is Uwe Vincenz.

Ms. Vincenz, wife of Uwe, founded the Institute of Applied Technology, who is our new Joint Venture partner RENON, in Germany. Uwe is the lead developer; he graduated from the Technical University Chemnitz with a degree in mechanical engineering. He also is a Master Mechanic specializing in heating and sanitary technology. He personally developed major portions of the hybrid technology including system components and contributes additional technical improvements as part of the overall RENON strategy. Mr. Vincenz has designed and executed major energy and heating projects in Germany, Switzerland, Russia and China.

About RENON: We are excited to introduce a unique and revolutionary invention in the employment of solar energy: the Hybrid Power Collector System. This ground-breaking innovation combines existing solar systems into an exceptional hybrid which is capable of maximizing the effectiveness of the traditional solar panels. Until recently solar collectors could be used in two ways: the different light spectrums were used separately for energy production, either for producing electricity or heat energy. Traditional Photovoltaic systems use the visible part of light and deliver electricity. Solarthermics transform the invisible infrared spectrum into heat for heating purposes and warm water.

Further information can be obtained by phoning Jeffrey R. Bruhjell +1 406 558 4947 or by visiting or Uwe Vincenz, Telefon: +49 3447 834448 or email:

Safe Harbour Statement

This communication contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Global Immune Technologies, Inc. and members of its management as well as the assumptions on which such statements are based.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions.

The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE Global Immune Technologies, Inc.